On Thursday night I attended Dr. Nancy Snydermen speech about media and health and what it is like to be a medical viagra cialis online pharmacy pharmacy and work as a journalist as well (She was the distinguished speaker for the 19th annual Jessica Savitch distinguished journalism lecture series). Dr. Nancy Snyderman gave information that was beneficial to two types of people: the journalist/broadcasters and the biologist/scientist. It was interesting to see a mix of both of these things and it was even more interesting to hear Dr. Nancy Snyderman explain how she got to that position and the type of issues and circumstances she finds her self in as a medical doctor and a medical reporter.
Dr. Snyderman started of her speech explaining how she always knew she always wanted to be a medical doctor since she was three years old. Throughout the years she pursed her medical dream by attending the University of Nebraska medical school. Afterward she specialized in ear, nose and throat surgery. She explained, however that her local news recorded her a few times for the nightly news, and the producer told her that she was pretty good at explaining things. So she decided that she would pitch the idea of becoming a medical reporter to ABC and its affiliates news. In the end she worked for ABC as a correspondent for 17 years. She was featured on 20/20, Primetime, and Good Morning America (I have watched several episodes of these shows were she was on an episode). Following her career at she discussed her move to MSNBC. She discussed some of the aspects of her job and how competition was more prevalent in some settings and not in others. She explained how sometimes her medical career and her reporting career came into conflict with each other. She used the example of the Haiti disaster. She had to put her doctor “hat” on although she was there for a reporting job form MSNBC she did not let that stop her for utilizing her medical skills. In fact she had to amputate a young mans arm because she knew that was the best thing for him. She saves lives and she reports and sometimes she has to do both. She ended her speech explaining how she still works for the staff of University of Pennsylvania ears, nose, and throat department. She closed it explaining how we can all really live any dream we want as long as we put our mind to it.
This week I focused on the audience’s response to the performers. The audience seemed so compelled by her speech and her work. They were so interested. The line for questions was extremely long and we had to cut it short. Which indicated to me that the audience really loved her and her message. Her visual aids were so emotional and personal and it really showed us that she loved her job. It made her presentation even more relatable.
I really enjoyed this speech. It has really changed me views about my career yes. I still want to be a medical doctor, but Dr. Nancy Snyderman just opened up a new field and aspect that I never thought about. This event really addresses our goals of becoming a more active Ithaca college member. I would absolutely recommend this event to other people it was so informative, yet very compelling.
Tuesday, November 1, 2011
Saturday, October 29, 2011
Fastest way to Increase Small Size of Penis and How to Increase the Penis Size
Men of all ages, social rank and people have always been worried about the size of their penises. Most cultures around the globe consider the large online pharmacy as a sign of manhood, potency, power and health.Now, men can enlarge their penises thanks to the numerous penis enlargement options provide by modern technologies such as: penis enlargement techniques and pe pills, as well as natural penis enlargement medications.
These methods offer a natural enlargement of the penis both in length and girth.
http://www.herbalcureindia.com/male-health/penis-enlargement.html
Very often, the choice of the most suitable option is quite difficult when there are so many diverse alternatives to choose from. Some of the obtainable penis enlargement methods like penis enlargement pills and surgery are quite classy and they require some time.
Increase Penis Exercises
1. Jelqing. Jelqing is probably the most ancient male improvement technique (it was used by nomadic Arabian tribes.) It involves actions similar to "milking" your penis to increase the amount of blood, which fills Corpora Covernosa (the part of your penis that is filled with blood and enlarged during erections) thus creation your penis visibly larger.
The important fact is that jelqing, if performed habitually, can enduringly increase the size of Corpora Covernosa and thus your penis size (both length and girth).
2. Penis Stretching. There are several type of penis stretching exercises but their basic principle is the same: stretching the tissues of your penis. Stretching makes cells composing your penis grow growing the length and girth (lesser effect) of your penis.
3. Kegel Exercises. These exercises are not targeted at the penis itself but rather at the pubococcygeus muscle, which is used to delay erections. Thus, if you train this muscle, you will be able to make longer your erections.
Treatment of Increase Penis
Male hormone testosterone replacement: The stand-in of male hormone testosterone is one of the common treatments for penis enlargement. The various grounding of testosterone is:
Oral preparation, which is accessible in capsule form. It needs to be given one to three capsules daily. These have no side effects.
Tran dermal Testosterone given as scrotal patch. It is very effective & has no side effects. It can be also given as Testosterone gel, which can be functional on any part of the skin.
Sublingual Testosterone cyclodextrin is now available which is very fast acting & very effective is fast & better sex organ & secondary sexual nature development.
Home Remedies for Increase Penis Size
Use a program that visually illustrates the exercise you need to do, so you can easily perform each step in the comfort of your home.
Also try to find a program that comes with customer support.
A support forum where you can ask questions and swap opinion with other people who are trying the same thing is even more important.
As you will be interact with some more experienced members that have already gained inches. This helps in giving you that added force to achieve your desired penis size.
A money back guarantee gives you calm of mind and makes it risk free to you.
The good news is there is no longer any bewilderment over which technique is the best usual male enhancement for men.
Read more on Penis Enlargement and Premature Ejaculation and Erectile Dysfunction
Tuesday, May 3, 2011
Interim results for phase 1b trial on Presidio Pharmaceuticals' PPI-461HCV NS5A Inhibitor
Data from EASL will be coming in fast and hard in the coming days. Here, San Fran-based Presidio Pharmaceuticals talks about interim Phase 1b results from PPI-461, one of the promising compounds from it's novel NS5A cheap cialis program. Usually, interim data on a Phase 1b trial doesn't mean a whole lot, but PPI-461 has a unique mechanism of action, not much to report in terms of adverse events, and is active against seven genotypes. One more thing - the fact that one Tx-naive patient had baseline resistance to PPI-461 is concerning, however, and probably deserves further investigation on it's own.
Mar. 30, 2011 (Business Wire) -- Presidio Pharmaceuticals, Inc. announced today positive preliminary results from a Phase 1b clinical trial of PPI-461, a novel HCV NS5A cialis for the treatment of patients with chronic hepatitis C.
The PPI-461 phase 1b clinical trial reported here is a multiple ascending dose, randomized, blinded, placebo-controlled study in treatment-naïve adult hepatitis C patients with HCV genotype-1 infection; this trial is presently ongoing in the U.K., Denmark, and the United States. The study objectives are to assess the safety, tolerability, pharmacokinetics, and initial antiviral effects of PPI-461 during once-daily (QD) dosing at three dosing levels (50, 100, and 200 mg/day) for three days. Each dosing cohort of 8 patients is randomized 6 (PPI-461):2 (placebo). Two dosing groups have completed study treatment to date; the third (200 mg) dosing group is ongoing.
The interim Phase 1b trial results indicate that PPI-461 has been well-tolerated, with no serious or severe adverse events and no modifications or premature discontinuations of study treatment. Among PPI-461 recipients there have been only transient clinical adverse events, of non-specific types commonly seen in clinical trials, with no dose-related or treatment-related patterns of specific adverse events or laboratory abnormalities.
Pharmacokinetic (PK) analyses of patients’ PPI-461 blood levels indicate that substantial blood levels of PPI-461 have been achieved rapidly and are dose proportional. Importantly, blood levels that are inhibitory for HCV replication have been maintained throughout the 24-hr inter-dose periods in the study patients.
Virologic data from the first two dosing groups indicate rapid and marked reductions in patients’ serum viral loads (HCV RNA levels), in both dosing groups, in the first two days of treatment. The 50 mg dosing group achieved a mean maximal HCV RNA reduction of 3.1 log10 IU/mL (5 of 6 patients), while the 100 mg group achieved a mean maximal HCV RNA reduction of 3.7 log10 IU/mL (6 of 6 patients). The mean maximal HCV RNA reduction for 4 Placebo treated patients was 0.3 log10 IU/mL. One patient in the 50 mg cohort had a negligible response to PPI-461(0.4 log10 IU/mL HCV RNA reduction). This patient entered the study with highly resistant virus, as evidenced by NS5A resistance substitutions (L31M, Y93N, L28F, R30N) detected at high levels in pre-treatment sera. Such a patient would be expected to have minimal efficacy with any NS5A inhibitor, since these agents share common key resistance mutations, as will be reported in a Presidio presentation at the 2011 annual meeting of the European Association for the Study of Liver Disease (EASL) in Berlin on April 2nd (R. Colonno et al., poster #1199).
“These positive clinical data for PPI-461 in hepatitis C patients further support the inclusion of NS5A inhibitors in clinical development of novel combination therapies. Such future combination therapies are expected to substantially improve patient outcomes and should help stem the rising incidence of HCV-associated severe liver disease and premature mortality,” said Nathaniel A. Brown, M.D., Presidio’s Chief Medical Officer.
The final results of the completed Phase 1b trial of PPI-461 will be submitted for presentation at a scientific meeting later this year.
About Presidio’s HCV NS5A Inhibitors
Inhibitors of the HCV NS5A protein represent an exciting, highly potent class that is mechanistically distinct from other classes of direct-acting HCV antivirals that target the viral protease or replicase (polymerase).
PPI-461 is the first in a series of novel and selective HCV NS5A inhibitors discovered by Presidio Pharmaceuticals. Presidio’s NS5A candidates are selected from numerous internal discovery leads, based on their potent activity against all major HCV genotypes and their potential for once-daily dosing with good tolerance. A Presidio presentation at the 2011 annual meeting of EASL in Berlin on April 2nd (R. Colonno et al., Poster #1200) will highlight the preclinical profile of three other novel NS5A inhibitors in development by Presidio, which derive from distinct chemical series.
About Presidio
Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical stage specialty pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics for novel and validated targets. For more information, please visit our website at: www.presidiopharma.com.
Presidio Pharmaceuticals, Inc.
Omar K. Haffar, PhD, 415-655-7561
omar@presidiopharma.com
Mar. 30, 2011 (Business Wire) -- Presidio Pharmaceuticals, Inc. announced today positive preliminary results from a Phase 1b clinical trial of PPI-461, a novel HCV NS5A cialis for the treatment of patients with chronic hepatitis C.
The PPI-461 phase 1b clinical trial reported here is a multiple ascending dose, randomized, blinded, placebo-controlled study in treatment-naïve adult hepatitis C patients with HCV genotype-1 infection; this trial is presently ongoing in the U.K., Denmark, and the United States. The study objectives are to assess the safety, tolerability, pharmacokinetics, and initial antiviral effects of PPI-461 during once-daily (QD) dosing at three dosing levels (50, 100, and 200 mg/day) for three days. Each dosing cohort of 8 patients is randomized 6 (PPI-461):2 (placebo). Two dosing groups have completed study treatment to date; the third (200 mg) dosing group is ongoing.
The interim Phase 1b trial results indicate that PPI-461 has been well-tolerated, with no serious or severe adverse events and no modifications or premature discontinuations of study treatment. Among PPI-461 recipients there have been only transient clinical adverse events, of non-specific types commonly seen in clinical trials, with no dose-related or treatment-related patterns of specific adverse events or laboratory abnormalities.
Pharmacokinetic (PK) analyses of patients’ PPI-461 blood levels indicate that substantial blood levels of PPI-461 have been achieved rapidly and are dose proportional. Importantly, blood levels that are inhibitory for HCV replication have been maintained throughout the 24-hr inter-dose periods in the study patients.
Virologic data from the first two dosing groups indicate rapid and marked reductions in patients’ serum viral loads (HCV RNA levels), in both dosing groups, in the first two days of treatment. The 50 mg dosing group achieved a mean maximal HCV RNA reduction of 3.1 log10 IU/mL (5 of 6 patients), while the 100 mg group achieved a mean maximal HCV RNA reduction of 3.7 log10 IU/mL (6 of 6 patients). The mean maximal HCV RNA reduction for 4 Placebo treated patients was 0.3 log10 IU/mL. One patient in the 50 mg cohort had a negligible response to PPI-461(0.4 log10 IU/mL HCV RNA reduction). This patient entered the study with highly resistant virus, as evidenced by NS5A resistance substitutions (L31M, Y93N, L28F, R30N) detected at high levels in pre-treatment sera. Such a patient would be expected to have minimal efficacy with any NS5A inhibitor, since these agents share common key resistance mutations, as will be reported in a Presidio presentation at the 2011 annual meeting of the European Association for the Study of Liver Disease (EASL) in Berlin on April 2nd (R. Colonno et al., poster #1199).
“These positive clinical data for PPI-461 in hepatitis C patients further support the inclusion of NS5A inhibitors in clinical development of novel combination therapies. Such future combination therapies are expected to substantially improve patient outcomes and should help stem the rising incidence of HCV-associated severe liver disease and premature mortality,” said Nathaniel A. Brown, M.D., Presidio’s Chief Medical Officer.
The final results of the completed Phase 1b trial of PPI-461 will be submitted for presentation at a scientific meeting later this year.
About Presidio’s HCV NS5A Inhibitors
Inhibitors of the HCV NS5A protein represent an exciting, highly potent class that is mechanistically distinct from other classes of direct-acting HCV antivirals that target the viral protease or replicase (polymerase).
PPI-461 is the first in a series of novel and selective HCV NS5A inhibitors discovered by Presidio Pharmaceuticals. Presidio’s NS5A candidates are selected from numerous internal discovery leads, based on their potent activity against all major HCV genotypes and their potential for once-daily dosing with good tolerance. A Presidio presentation at the 2011 annual meeting of EASL in Berlin on April 2nd (R. Colonno et al., Poster #1200) will highlight the preclinical profile of three other novel NS5A inhibitors in development by Presidio, which derive from distinct chemical series.
About Presidio
Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical stage specialty pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics for novel and validated targets. For more information, please visit our website at: www.presidiopharma.com.
Presidio Pharmaceuticals, Inc.
Omar K. Haffar, PhD, 415-655-7561
omar@presidiopharma.com
the most popular treatment for erectile dysfunction. Cialis works by helping blood flow
See also: cheap cialis |
FDA Approves Top-Selling Antidepressant Medication To Treat Chronic Pain
cialis Him to us cheap cialis the Saga of the Outlaw
.
FDA Approves Top-Selling Antidepressant Medication To Treat Chronic Pain
cialis Him to us cheap cialis the Saga of the Outlaw
.
Subscribe to:
Posts (Atom)